Become A Featured Company

Cannabinoids May Do More Than Manage Cancer Symptoms

Ryan Allway

July 24th, 2018

Exclusive, News, Top News

The liberalization of cannabis laws around the world has opened the door for researchers to explore the therapeutic benefits of cannabinoids. While GW Pharmaceuticals plc (NASDAQ: GWPH) has already launched products targeting epilepsy and spasticity in Multiple Sclerosis, emerging research suggests that they could play a role in treating many types of cancers.

In this article, we will look at how cannabinoids are currently being used by physicians and how companies, such as Pascal Biosciences Inc. (TSX-V: PAS), are exploring new treatment options and combination therapies.

Pain & Appetite Stimulation

Cannabinoids have been primarily used by physicians to treat the side-effects of cancer. For example, cannabinoids have a well known anti-inflammatory effect that helps reduce pain, while animal studies have strongly suggested that tetrahydrocannabinol (THC) and other cannabinoids can help stimulate appetite and prevent vomiting caused by certain types of chemotherapy.

The most common cancer-related indications with approved drugs around the world include:

  • Stimulating appetite.
  • Pain relief.
  • Nausea and vomiting.
  • Anxiety and sleep.

Dronabinol and Nabilone were both approved by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-related nausea and vomiting in patients that have not responded to conventional therapies. These drugs were possible because they are synthetic cannabinoids created in a lab rather than natural cannabinoids isolated directly from the cannabis plant.

Potential Anticancer Activity

Researchers have been actively studying cannabinoids to see if they could be beneficial in the treatment of cancer rather than just its side effects.

Cannabinoids have numerous possible effects that could play a role in cancer treatment, according to Cancer.gov:

  • Anti-inflammatory activity.
  • Blocking cell growth.
  • Preventing the growth of blood vessels that supply tumors.
  • Antiviral activity.

There are more than 3,000 studies published on Google Scholar in 2018 alone, with many more that have been published in prior years. These studies address everything from treating cancer symptoms to destroying cancer cells by exposing them to cannabinoid compounds.

Research in the United States has been hindered by the requirement for any researchers interested in studying the drug to obtain a Schedule I license from the Drug Enforcement Administration (DEA) and approval from the National Institute on Drug Abuse (NIDA). However, there are a growing number of scientists in other jurisdictions with more favorable laws, including Canada, where medical cannabis is federally legal.

In June, the company announced that it received a license from the U.S. DEA to conduct research and development on cannabinoids. As one of a few organizations with a Schedule I researcher license, the company is positioning itself to become a leader in cannabinoid drug development. The company also renewed its UBC collaboration and continues to financially support Dr. Wilfred Jefferies’ laboratory at the Michael Smith Laboratories.

Immunotherapy Possibilities

Pascal Biosciences Inc. (TSX-V: PAS) believes that cannabinoids could also play a role in helping existing immunotherapy drugs better target cancer cells. In February, the company announced the discovery of certain cannabinoids that enhanced the immunogenicity of tumor cells, which rendered them more susceptible to recognition by the immune system. The discovery is important because it can be used with a new class of cancer fighting agents — known as checkpoint inhibitors.

“We are very excited about this novel discovery,” commented Dr. Patrick Gray, CEO of Pascal Biosciences. “Cannabinoids typically have good pharmacological properties, as most have low toxicity and are easily absorbed into the blood, which are great advantages for drug development. We have tested hundreds of natural and synthetic cannabinoids in our proprietary assay. This will enable us to soon determine an optimal product. In combination with immune checkpoint inhibitors, cannabinoids may significantly improve cancer care. We look forward to soon translating our results into clinical studies.”

Looking Ahead

Pascal Biosciences Inc. (TSX-V: PAS) represents a unique investment opportunity in the cancer treatment space. After making its discovery and obtaining a DEA license, the company is well positioned to advance its research programs and ultimately generate long-term value for shareholders. Last week, Pascal appointed Julie Eastland, an accomplished financial executive, to the Board of Directors. Ms. Eastland is a seasoned strategic and financial executive with more than 25 years of experience in public and private biotechnology companies. “Ms. Eastland has strong relationships with investors, investment bankers and analysts covering the U.S. public biotech sector, and excellent experience in partnering, acquisitions, collaborations, and licensing. She will work closely with Pascal to align our scientific strategy with our financial goals,” stated Dr. Patrick Gray, CEO of Pascal.
For more information, visit the company’s website at www.pascalbiosciences.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading